Galmed Pharmaceuticals Shareholders Approve Proposal at Special Meeting

The latest update is out from Galmed Pharmaceuticals ( (GLMD) ).

On March 5, 2026, Galmed Pharmaceuticals held a Special General Meeting of Shareholders at which investors voted on a single proposal previously outlined in a February 9, 2026 proxy statement. The proposal received the requisite majority under Israeli Companies Law, enabling the company to proceed with its planned corporate or governance action and signaling solid shareholder support. The outcome is also being incorporated into several of Galmed’s existing SEC registration statements, maintaining regulatory alignment for its share plans and potential future securities offerings.

The most recent analyst rating on (GLMD) stock is a Hold with a $0.68 price target. To see the full list of analyst forecasts on Galmed Pharmaceuticals stock, see the GLMD Stock Forecast page.

Spark’s Take on GLMD Stock

According to Spark, TipRanks’ AI Analyst, GLMD is a Neutral.

The score is weighed down mainly by weak financial performance (no revenue, ongoing losses, and continued cash burn), with technicals also bearish as the stock trades below all major moving averages and momentum indicators remain negative. A debt-free balance sheet provides some stabilization but is not enough to offset the core operating risks.

To see Spark’s full report on GLMD stock, click here.

More about Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing therapeutic candidates, historically in liver and metabolic diseases. The Israel-based firm is listed in the United States and uses SEC registration statements to support equity-based compensation plans and potential capital-raising activities in global markets.

Average Trading Volume: 86,430

Technical Sentiment Signal: Strong Sell

Current Market Cap: $3.35M

Find detailed analytics on GLMD stock on TipRanks’ Stock Analysis page.